Radiopharmaceuticals Market
Radiopharmaceuticals uptake receiving traction amid Increasing Patient awareness, disease-targeted cancer therapy, and use of molecular imaging
Radiopharmaceuticals Market by Radioisotope Type, Application, Source, End-user, Region & Forecast 2022 to 2032
Radiopharmaceuticals Market Snapshot (2022 to 2032)
[190 Pages Report] According to Future Market Insights (FMI), the radiopharmaceuticals market would be worth US$ 6.2 Billion in 2022. During the forecast period ranging from 2022 to 2032, radiopharmaceuticals uptake is anticipated to flourish at a value CAGR of 4.3% to reach US$ 9.5 Billion.
Because of the rising frequency of cancer cases and the expansion of the healthcare industry in the United States and Canada, North America will account for more than 47% of the worldwide market.
According to Future Market Insights, notable participants include Siemens AG, General Electric Co. (GE Healthcare), Curium, Lantheus Holdings, Inc., and Eckert & Ziegler. In the worldwide radiopharmaceuticals market, the top companies account for over 90% of revenue.
|
Data Points |
Key Statistics |
|
Radiopharmaceuticals Market Value 2022 |
US$ 6.2 Billion |
|
Radiopharmaceuticals Market Projected Value (2032) |
US$ 9.5 Billion |
|
Radiopharmaceuticals Market CAGR (2022 to 2032) |
4.3% |
Let us know your requirement to get
100% FREE customization
Radiopharmaceuticals Demand Analysis (2016 to 2021) Vs Market Outlook (2022 to 2032)
The global demand for radiopharmaceuticals projected to increase at a CAGR of 4.3% during the forecast period between 2022 and 2032, reaching a total of US$ 9.5 Billion in 2032, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 3.8%.
Improving radio-therapeutic penetration is predicted to be the primary driver of the radiopharmaceuticals market. Radiopharmaceuticals are rapidly being utilized to diagnose and treat a variety of ailments, including cancer, cardiovascular disease, and neurological problems. Radiopharmaceuticals are widely utilized in the treatment of certain disorders due to the properties of radioactive decay and the possibility of focused therapeutic irradiation. However, the unusual outbreak of COVID-19 hampered market expansion.
Radioisotope production has been ceased worldwide, as have research efforts. The worldwide market value fell as a result of disruptions in the demand and supply chains. The rapid use of sophisticated nuclear imaging technologies such as SPECT and Positron Emission Tomography (PET) will considerably contribute to market development. Radiopharmaceuticals market expansion is being aided by increased research and development from key players.
GE Healthcare, for example, provided cloud and IT-based solutions and apps to link medical imaging with analytics and insights. The growing clinical uses of radiopharmaceuticals in cancer, cardiology, endocrinology, and neurology are boosting market growth.
Which Drivers underpin Radiopharmaceuticals Industry Expansion?
Developing Centralized Pharmacies to Support Growth
There is a dearth of codified good manufacturing practice (GMP) requirements in the radiopharmaceutical sector, as well as rigid laws controlling the use of radiopharmaceuticals. To solve quality assurance difficulties, nuclear medicine practitioners are advocating for the establishment of centralized radio-pharmacies.
This is because administrators and lawmakers are becoming increasingly interested in radiopharmaceutical, Positron Emission Tomography (PET), and clinical trial laws. A centralized radio pharmacy concept provides various benefits to patients and governing authorities, including the capacity to dispense patient-specific prescriptions and supply requested items from all sources and services accessible. These activities are projected to enhance market expansion throughout the forecast period.
Increasing Disease Prevalence is Accelerating the Market Growth
One of the prominent drivers fueling market expansion is the rising prevalence of acute and chronic illnesses such as cancer throughout the world as a result of numerous causes. Radiopharmaceuticals allow for the detection of tumor cells in organs or across the body. Cancer is the world's second largest cause of death.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhich Factors are limiting the Growth of Radiopharmaceuticals Market?
Expensive Costs Connected with R&D Capabilities to Impede the Market Growth
Expensive costs connected with R&D capabilities, inadequate infrastructure facilities, short half-life of radiopharmaceuticals, high equipment prices, and a lack of awareness in backward economies are predicted to stymie market expansion.
In addition, a lack of favourable reimbursement scenarios and technology penetration in developing economies, hospital budget cuts, particularly during pandemics, and a lack of suitable infrastructure in low- and middle-income countries are expected to pose challenges to the market during the forecast period.
Country-wise Insights
Will North America Continue Dominance in the Global Radiopharmaceuticals Market?
Increased Frequency of Cancer and Cardiovascular Illnesses to Fuel the Market Growth
Because of its large number of healthcare facilities, expanding overweight population, large patient population suffering from chronic diseases such as cancer, cardiovascular disorders, and strokes, and rising number of research activities, North America dominates the radiopharmaceuticals market.
The increased frequency of cancer and cardiovascular illnesses in the United States is driving the growth of the radiopharmaceuticals market. Nuclear medicine sales have increased due to an ageing population and bad lifestyle choices, which have resulted in an increase in cancer and obesity cases. Adoption of innovative radioisotope manufacturing methods to treat these disorders is expected to boost the country's radiopharmaceutical growth. The American Heart Association estimates that 17.3 million people die each year as a result of cardiovascular disease.
Radiopharmaceuticals provide radiologists an advantage in the treatment of various disorders. Targeted medicines and sophisticated technologies incorporated in cyclotrons for the treatment of cardiovascular disease and cancer will boost radiopharmaceutical demand in the United States. Based on the above, the United States will dominate the North American radiopharmaceuticals market throughout the projection period, accounting for more than 45% of market share.
Where does the growth of Radiopharmaceuticals Market in Asia Pacific Excluding Japan stand?
Expansion of the Healthcare Industry to fuel Market Growth
Product launches, acquisitions, distribution agreements, collaborations, and regional expansion by local firms, notably in India, are projected to boost the radiopharmaceuticals market in the Asia Pacific Excluding Japan.
The expansion of the healthcare industry and the adoption of improved technologies are the primary drivers of the radiopharmaceuticals market in India. Along with this, the country's high cancer prevalence has boosted the use of targeted medicines and enhanced radioisotope manufacturing.
The growing inclination for non-invasive medicines in India, as well as the great effectiveness provided by radiopharmaceuticals, is the primary reasons why radiopharmaceuticals are booming. Government and commercial healthcare organizations are expanding financing and R&D efforts to produce efficient tailored medicines with fewer adverse effects.
The incorporation of cutting-edge technology in the development of sophisticated radiotracers for the treatment of cancer and cardiovascular disease is assisting in the expansion. Several research projects launched by the National Cancer Institute have increased the manufacturing and use of radioisotopes for cancer therapy in India.
Why is the need for radiopharmaceuticals increasing in the United Kingdom?
Rising Incidences of Cancer in the Region to Accelerate Market
The United Kingdom is likely to be a major country in Europe, accounting for the largest proportion of the European radiopharmaceuticals market. Cancer is becoming more common in the United Kingdom resulting in increased production of radioisotopes for enhanced molecular imaging and cancer therapy treatments Radiopharmaceutical advantages, such as high effectiveness and non-invasive external monitoring, have encouraged radioisotope manufacturing.
According to a Cancer Research United Kingdom estimate, roughly 367,167 cancer cases are diagnosed in the United Kingdom. Every year, around 166,000 cancer deaths are documented. Rising scenarios like this are expected to promote the expansion of the country's radiopharmaceuticals industry. Expansion of healthcare infrastructure and more research on non-invasive targeted medicines to minimise the load would greatly increase radiopharmaceutical demand in the United Kingdom. The growing interest of healthcare professionals, administrators, and lawmakers in radiopharmaceutical, positron emission tomography, and clinical trial standards will undoubtedly boost market expansion.
A unified Market Research Subscription Platform, built for today's disparate research needs.
Category-wise Insights
Which is the most Popular Application of Radiopharmaceuticals?
The Oncology Segment to Drive the Radiopharmaceuticals Market
The increasing prevalence of cancer and cardiovascular disorders such as coronary heart disease and heart failure throughout the world is providing a boost to market expansion. Increasing incidence of lifestyle disorders, obesity, and tumours caused by poor behaviours among the elderly are the primary forces driving up demand for radiopharmaceuticals. According to Future Market Insights, Inc increased instances of breast cancer, lung cancer, and prostate cancer will drive sector growth.
The increasing use of nuclear medicine in cancer and cardiology is the primary driver of market expansion. According to the American Cancer Society, 1.9 million new cancer cases will be recorded in 2021, and about 608,570 people will die from cancer in the United States. With the number of cancer cases increasing, healthcare experts are creating innovative new approaches to produce nuclear medicine for therapy. Rapid adoption of sophisticated radiopharmaceutical methods for cancer treatment will drive growth.
Radiopharmaceuticals play an important role in cancer diagnosis and treatment by improving understanding of disease stages. According to Future Market Insights, the rising use of nuclear medicine in cancer will account for more than 50% of the worldwide market value by 2032.
The Start-Up Ecosystem: How key Players are opening Frontiers for Future Growth?
Start-ups and their innovations are driving some of the most recent advances in the radiopharmaceuticals sector. Radiopharmaceuticals gives the consumer a precise diagnosis and to highlight some of the companies. Let's have a look at some of the primary areas of innovation in this industry:
- Theragnostics, a British firm, creates radiopharmaceuticals based on fluorine-18. The primary medicine of the start-up, THG-008, is a fluorine-18 radiolabelled poly-ADP-ribose polymerase (PARP) inhibitor (rPARPi). It assists in the imaging of head and neck cancer as well as brain cancer. THG-009, an iodine rPARPi, is also being developed by the company.
- Navigo Proteins is a German business that creates innovative radio-conjugates. Affilin is a firm that creates artificial proteins that preferentially bind antigens and radio conjugates. This is accomplished by combining target-binding Affilin molecules with isotope-loaded chelators. The isotope-to-carrier ratios in the molecules are uniform. Researchers can fine-tune radio conjugates for theranostics by optimising the loaded radionuclide and the conjugate's specific half-life. In addition, the company is working on precision capture and precision targeting technologies, such as antibody purification and cellular treatment.
- Naogen Pharma, a French firm, is developing rubidium-82 generators for CAD diagnosis. The company produces Rubidium-82 radionuclide using a strontium-82/rubidium-82 infuser and a strontium-82/rubidium-82 generator. This is directly connected to the veins of patients. The equipment, together with a positron emission tomography (PET) system, can be installed on the patient's bed. In addition, the firm offers PET scanning, cardiac ischemia detection, and other services.
Who are the Leading Players in the Radiopharmaceuticals Market?
According to Future Market Insights, market consolidation has resulted from intense rivalry among top competitors. The top five market participants are Siemens AG, G E Healthcare, Curium, Lantheus Holdings Inc., and Eckert & Ziegler.
These top five players account for over 90% of the worldwide market share. The leading players' winning methods include providing innovative technology and nuclear medications for therapy.
Leading firms like as GE Healthcare and Siemens Healthcare are working on providing innovative product-based innovations, pharmaceutical services, and IT-based solutions in order to preserve their industry leadership.
Recent Developments:
- In March 2021, Aktis Oncology, a biotechnology firm developing a unique class of targeted radiopharmaceuticals to treat a wide spectrum of solid tumour cancer patients, reported the completion of a solid tumour series.
- In November 2020, Fusion Pharmaceuticals, a top Canadian radiopharmaceuticals business, announced cooperation with Anglo-Swedish Pharma giant AstraZeneca to commercialise and develop next-generation alpha emitting radiopharmaceuticals and combination treatments for cancer therapy.
Report Scope
|
Report Attribute |
Details |
|
Growth Rate |
CAGR of 4.3% from 2022 to 2032 |
|
Market Value in 2022 |
US$ 6.2 Billion |
|
Market Value in 2032 |
US$ 9.5 Billion |
|
Base Year for Estimation |
2021 |
|
Historical Data |
2016 to 2021 |
|
Forecast Period |
2022 to 2032 |
|
Quantitative Units |
Revenue in US$ Million and CAGR from 2022 to 2032 |
|
Report Coverage |
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization & Pricing |
Available upon Request |
Key Segments Covered in the Radiopharmaceuticals Industry Analysis
Radiopharmaceuticals Market by Radioisotope Type:
- Technetium-99
- Fluorine-18
- Iodine-131
- Leutetium-177
- Yttrium-90
- Gallium-68
- Gallium-67
- Rubidium-82
- Iodine-123
- Iodine-125
- Indium-111
- Others
Radiopharmaceuticals Market by Application:
- Oncology
- Cardiology
- Gastroenterology
- Neuroendocrinology
- Neurology
- Nephrology
- Others
Radiopharmaceuticals Market by Source:
- Cyclotrons
- Nuclear Reactors
Radiopharmaceuticals Market by End User:
- Hospitals
- Diagnostic Imaging Centers
- Ambulatory Surgical Centers
- Cancer Research Institute
Radiopharmaceuticals Market by Region:
- North America Radiopharmaceuticals Market
- Latin America Radiopharmaceuticals Market
- Western Europe Radiopharmaceuticals Market
- Eastern Europe Radiopharmaceuticals Market
- APEJ Radiopharmaceuticals Market
- Japan Radiopharmaceuticals Market
- Middle East & Africa Radiopharmaceuticals Market
Frequently Asked Questions
By 2022-end, sales of radiopharmaceuticals closed at a value of US$ 6.2 Billion.
From 2016 to 2021, radiopharmaceuticals demand expanded at a CAGR of 3.8%
From 2022 to 2032, radiopharmaceuticals sales are expected to flourish at a CAGR of 4.3%
By 2032, the market value of radiopharmaceuticals expected to reach US$ 9.5 Billion
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Global Market Share Analysis
1.3. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Macro-Economic Factors
3.1.1. Increasing healthcare expenditure as a percentage of GDP
3.1.2. Rise in Aging population
3.2. Forecast Factors - Relevance & Impact
3.2.1. Increasing Installed base for PET and SPECT Scanners
3.2.2. Increasing Incidence of Cancer
3.2.3. Increasing Diagnosis Rate
3.3. Market Dynamics
3.3.1. Opportunity Analysis
3.3.2. Drivers
3.3.3. Restraints
3.3.4. Trends
4. Market Context
4.1. Reimbursement Scenario
4.2. Key Regulations
4.3. Value Chain Analysis
5. Global Market Demand (Size in US$ Mn) Analysis 2016-2021 and Forecast, 2022-2032
5.1. Historical Market Value (US$ Mn) Analysis, 2016-2021
5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
5.2.1. Y-o-Y Growth Trend Analysis
5.2.2. Absolute $ Opportunity Analysis
5.3. Market Value Growth Comparison
6. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Radioisotope
6.1. Introduction / Key Findings
6.2. Historical Market Size (US$ Mn) Analysis By Radioisotope, 2016-2021
6.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Radioisotope, 2022-2032
6.3.1. Technetium-99
6.3.2. Fluorine-18
6.3.3. Iodine-131
6.3.4. Leutetium-177
6.3.5. Yttrium-90
6.3.6. Gallium-68
6.3.7. Gallium-67
6.3.8. Rubidium-82
6.3.9. Iodine-123
6.3.10. Iodine-125
6.3.11. Indium-111
6.3.12. Others
6.4. Market Attractiveness Analysis By Radioisotope
7. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Application
7.1. Introduction / Key Findings
7.2. Historical Market Size (US$ Mn) Analysis By Application, 2016-2021
7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2022-2032
7.3.1. Oncology
7.3.2. Cardiology
7.3.3. Gastroenterology
7.3.4. Neuroendocrinology
7.3.5. Neurology
7.3.6. Nephrology
7.3.7. Others
7.4. Market Attractiveness Analysis By Application
8. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Source
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Source, 2016-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Source, 2022-2032
8.3.1. Cyclotrons
8.3.2. Nuclear Reactors
8.4. Market Attractiveness Analysis By Source
9. Global Market Analysis 2016-2021 and Forecast 2022-2032, by End User
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2016-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022-2032
9.3.1. Hospitals
9.3.2. Diagnostic Imaging Centers
9.3.3. Ambulatory Surgical Centers
9.3.4. Cancer Research Institute
9.4. Market Attractiveness Analysis By End User
10. Global Market Analysis 2016-2021 and Forecast 2022-2032, by Region
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2016-2021
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2022-2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Western Europe
10.3.4. Eastern Europe
10.3.5. APEJ
10.3.6. Japan
10.3.7. MEA
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2016-2021 and Forecast 2022-2032
11.1. Introduction
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
11.3.1. By Country
11.3.1.1. U.S.
11.3.1.2. Canada
11.3.2. By Radioisotope
11.3.3. By Application
11.3.4. By Source
11.3.5. By End User
11.4. Market Attractiveness Analysis
11.4.1. By Country
11.4.2. By Radioisotope
11.4.3. By Application
11.4.4. By Source
11.4.5. By End User
12. Latin America Market Analysis 2016-2021 and Forecast 2022-2032
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
12.3.1. By Country
12.3.1.1. Brazil
12.3.1.2. Mexico
12.3.1.3. Rest of Latin America
12.3.2. By Radioisotope
12.3.3. By Application
12.3.4. By Source
12.3.5. By End User
12.4. Market Attractiveness Analysis
12.4.1. By Country
12.4.2. By Radioisotope
12.4.3. By Application
12.4.4. By Source
12.4.5. By End User
13. Western Europe Market Analysis 2016-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
13.3.1. By Country
13.3.1.1. Germany
13.3.1.2. U.K
13.3.1.3. France
13.3.1.4. Spain
13.3.1.5. Italy
13.3.1.6. Nordic Countries
13.3.1.7. Benelux
13.3.1.8. Rest of Western Europe
13.3.2. By Radioisotope
13.3.3. By Application
13.3.4. By Source
13.3.5. By End User
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Radioisotope
13.4.3. By Application
13.4.4. By Source
13.4.5. By End User
14. Eastern Europe Market Analysis 2016-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast by Market Taxonomy, 2022-2032
14.3.1. By Country
14.3.1.1. Russia
14.3.1.2. Poland
14.3.1.3. Rest of EE
14.3.2. By Radioisotope
14.3.3. By Application
14.3.4. By Source
14.3.5. By End User
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Radioisotope
14.4.3. By Application
14.4.4. By Source
14.4.5. By End User
15. APEJ Market Analysis 2016-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
15.3.1. By Country
15.3.1.1. China
15.3.1.2. India
15.3.1.3. Australia & New Zealand
15.3.1.4. ASEAN
15.3.1.5. Rest of APEJ
15.3.2. By Radioisotope
15.3.3. By Application
15.3.4. By Source
15.3.5. By End User
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Radioisotope
15.4.3. By Application
15.4.4. By Source
15.4.5. By End User
16. Japan Market Analysis 2016-2021 and Forecast 2022-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
16.3.1. By Radioisotope
16.3.2. By Application
16.3.3. By Source
16.3.4. By End User
16.4. Market Attractiveness Analysis
16.4.1. By Radioisotope
16.4.2. By Application
16.4.3. By Source
16.4.4. By End User
17. Middle East and Africa Market Analysis 2016-2021 and Forecast 2022-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2016-2021
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2022-2032
17.3.1. By Country
17.3.1.1. GCC Countries
17.3.1.2. South Africa
17.3.1.3. Rest of MEA
17.3.2. By Radioisotope
17.3.3. By Application
17.3.4. By Source
17.3.5. By End User
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Radioisotope
17.4.3. By Application
17.4.4. By Source
17.4.5. By End User
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. Siemens AG (Siemens Healthineers)
18.3.1.1. Overview
18.3.1.2. Service Portfolio
18.3.1.3. Profitability by Market Segments (Service/Channel/Region)
18.3.1.4. Sales Footprint
18.3.1.5. Strategy Overview
18.3.1.5.1. Marketing Strategy
18.3.1.5.2. Service Strategy
18.3.1.5.3. Channel Strategy
18.3.2. Positron Corporation
18.3.2.1. Overview
18.3.2.2. Service Portfolio
18.3.2.3. Profitability by Market Segments (Service/Channel/Region)
18.3.2.4. Sales Footprint
18.3.2.5. Strategy Overview
18.3.2.5.1. Marketing Strategy
18.3.2.5.2. Service Strategy
18.3.2.5.3. Channel Strategy
18.3.3. Novartis (Advanced Accelerator Applications)
18.3.3.1. Overview
18.3.3.2. Service Portfolio
18.3.3.3. Profitability by Market Segments (Service/Channel/Region)
18.3.3.4. Sales Footprint
18.3.3.5. Strategy Overview
18.3.3.5.1. Marketing Strategy
18.3.3.5.2. Service Strategy
18.3.3.5.3. Channel Strategy
18.3.4. Curium
18.3.4.1. Overview
18.3.4.2. Service Portfolio
18.3.4.3. Profitability by Market Segments (Service/Channel/Region)
18.3.4.4. Sales Footprint
18.3.4.5. Strategy Overview
18.3.4.5.1. Marketing Strategy
18.3.4.5.2. Service Strategy
18.3.4.5.3. Channel Strategy
18.3.5. GE Healthcare
18.3.5.1. Overview
18.3.5.2. Service Portfolio
18.3.5.3. Profitability by Market Segments (Service/Channel/Region)
18.3.5.4. Sales Footprint
18.3.5.5. Strategy Overview
18.3.5.5.1. Marketing Strategy
18.3.5.5.2. Service Strategy
18.3.5.5.3. Channel Strategy
18.3.6. Lantheus Holdings, Inc.
18.3.6.1. Overview
18.3.6.2. Service Portfolio
18.3.6.3. Profitability by Market Segments (Service/Channel/Region)
18.3.6.4. Sales Footprint
18.3.6.5. Strategy Overview
18.3.6.5.1. Marketing Strategy
18.3.6.5.2. Service Strategy
18.3.6.5.3. Channel Strategy
18.3.7. Sotera Health LLC (Nordion, Inc.)
18.3.7.1. Overview
18.3.7.2. Service Portfolio
18.3.7.3. Profitability by Market Segments (Service/Channel/Region)
18.3.7.4. Sales Footprint
18.3.7.5. Strategy Overview
18.3.7.5.1. Marketing Strategy
18.3.7.5.2. Service Strategy
18.3.7.5.3. Channel Strategy
18.3.8. Bayer AG
18.3.8.1. Overview
18.3.8.2. Service Portfolio
18.3.8.3. Profitability by Market Segments (Service/Channel/Region)
18.3.8.4. Sales Footprint
18.3.8.5. Strategy Overview
18.3.8.5.1. Marketing Strategy
18.3.8.5.2. Service Strategy
18.3.8.5.3. Channel Strategy
18.3.9. Eckert & Ziegler
18.3.9.1. Overview
18.3.9.2. Service Portfolio
18.3.9.3. Profitability by Market Segments (Service/Channel/Region)
18.3.9.4. Sales Footprint
18.3.9.5. Strategy Overview
18.3.9.5.1. Marketing Strategy
18.3.9.5.2. Service Strategy
18.3.9.5.3. Channel Strategy
19. Assumptions and Acronyms Used
20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 01: Global Market Value (US$ Mn) Growth Comparison
Table 02: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Radioisotope
Table 03: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Application
Table 04: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Source
Table 05: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By End User
Table 06: Global Market Value (US$ Mn) Analysis and Opportunity Assessment 2022-2032, By Region
Table 07: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country
Table 08: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope
Table 09: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application
Table 10: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source
Table 11: North America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User
Table 12: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country
Table 13: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope
Table 14: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application
Table 15: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source
Table 16: Latin America Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User
Table 17: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country
Table 18: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope
Table 19: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application
Table 20: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source
Table 21: Western Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User
Table 22: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country
Table 23: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope
Table 24: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application
Table 25: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source
Table 26: Eastern Europe Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User
Table 27: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country
Table 28: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope
Table 29: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application
Table 30: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source
Table 31: APEJ Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User
Table 32: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope
Table 33: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application
Table 34: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source
Table 35: Japan Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User
Table 36: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Country
Table 37: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Radioisotope
Table 38: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Application
Table 39: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By Source
Table 40: MEA Market Value (US$ Mn) Analysis 2016-2021 and Forecast 2022-2032, By End User
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 01: Global Market Revenue Share by Radioisotope, 2021E & 2031F
Figure 02: Global Market Revenue Share by Application, 2021E & 2031F
Figure 03: Global Market Revenue Share by Source, 2021E & 2031F
Figure 04: Global Market Revenue Share by End User, 2021E & 2031F
Figure 05: Global Market Revenue Share by Region, 2021E & 2031F
Figure 06: Market Value Analysis and Forecast 2021 – 2031 (US$ Mn)
Figure 07: Market Value (US$ Mn), 2016 – 2020
Figure 08: Market Absolute $ Opportunity (US$ Mn), 2022-2032
Figure 09: Comparison February 2017 and October 2021, Y-o-Y Forecast
Figure 10: Global Market Share Analysis (%), By Radioisotope, 2021 & 2031
Figure 11: Global Market Y-o-Y Analysis (%), By Radioisotope, 2022-2032
Figure 12: Global Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 13: Global Market Share Analysis (%), By Application, 2021 & 2031
Figure 14: Global Market Y-o-Y Analysis (%), By Application, 2022-2032
Figure 15: Global Market Attractiveness Analysis by Application, 2022-2032
Figure 16: Global Market Share Analysis (%), By Source, 2021 & 2031
Figure 17: Global Market Y-o-Y Analysis (%), By Source, 2022-2032
Figure 18: Global Market Attractiveness Analysis by Source, 2022-2032
Figure 19: Global Market Share Analysis (%), By End User, 2021 & 2031
Figure 20: Global Market Y-o-Y Analysis (%), By End User, 2022-2032
Figure 21: Global Market Attractiveness Analysis by End User, 2022-2032
Figure 22: Global Market Share Analysis (%), By Region, 2021 & 2031
Figure 23: Global Market Y-o-Y Analysis (%), By Region, 2022-2032
Figure 24: Global Market Attractiveness Analysis by Region, 2022-2032
Figure 25: North America Market Value Share, By Radioisotope (2022 E)
Figure 26: North America Market Value Share, By Application (2022 E)
Figure 27: North America Market Value Share, By Source (2022 E)
Figure 28: North America Market Value Share, By End User (2022 E)
Figure 29: North America Market Value Share, By Country (2022 E)
Figure 30: North America Market Value Analysis (US$ Mn), 2016-2021
Figure 31: North America Market Value Forecast (US$ Mn), 2022-2032
Figure 32: North America Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 33: North America Market Attractiveness Analysis by Application, 2022-2032
Figure 34: North America Market Attractiveness Analysis by Source, 2022-2032
Figure 35: North America Market Attractiveness Analysis by End User, 2022-2032
Figure 36: North America Market Attractiveness Analysis by Region, 2022-2032
Figure 37: Latin America Market Value Share, By Radioisotope (2022 E)
Figure 38: Latin America Market Value Share, By Application (2022 E)
Figure 39: Latin America Market Value Share, By Source (2022 E)
Figure 40: Latin America Market Value Share, By End User (2022 E)
Figure 41: Latin America Market Value Share, By Country (2022 E)
Figure 42: Latin America Market Value Analysis (US$ Mn),2016-2021
Figure 43: Latin America Market Value Forecast (US$ Mn), 2022-2032
Figure 44: Latin America Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 45: Latin America Market Attractiveness Analysis by Application, 2022-2032
Figure 46: Latin America Market Attractiveness Analysis by Source, 2022-2032
Figure 47: Latin America Market Attractiveness Analysis by End User, 2022-2032
Figure 48: Latin America Market Attractiveness Analysis by Region, 2022-2032
Figure 49: Western Europe Market Value Share, By Radioisotope (2022 E)
Figure 50: Western Europe Market Value Share, By Application (2022 E)
Figure 51: Western Europe Market Value Share, By Source (2022 E)
Figure 52: Western Europe Market Value Share, By End User (2022 E)
Figure 53: Western Europe Market Value Share, By Country (2022 E)
Figure 54: Western Europe Market Value Analysis (US$ Mn),2016-2021
Figure 55: Western Europe Market Value Forecast (US$ Mn), 2022-2032
Figure 56: Western Europe Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 57: Western Europe Market Attractiveness Analysis by Application, 2022-2032
Figure 58: Western Europe Market Attractiveness Analysis by Source, 2022-2032
Figure 59: Western Europe Market Attractiveness Analysis by End User, 2022-2032
Figure 60: Western Europe Market Attractiveness Analysis by Region, 2022-2032
Figure 61: Eastern Europe Market Value Share, By Radioisotope (2022 E)
Figure 62: Eastern Europe Market Value Share, By Application (2022 E)
Figure 63: Eastern Europe Market Value Share, By Source (2022 E)
Figure 64: Eastern Europe Market Value Share, By End User (2022 E)
Figure 65: Eastern Europe Market Value Share, By Country (2022 E)
Figure 66: Eastern Europe Market Value Analysis (US$ Mn),2016-2021
Figure 67: Eastern Europe Market Value Forecast (US$ Mn), 2022-2032
Figure 68: Eastern Europe Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 69: Eastern Europe Market Attractiveness Analysis by Application, 2022-2032
Figure 70: Eastern Europe Market Attractiveness Analysis by Source, 2022-2032
Figure 71: Eastern Europe Market Attractiveness Analysis by End User, 2022-2032
Figure 72: Eastern Europe Market Attractiveness Analysis by Region, 2022-2032
Figure 73: APEJ Market Value Share, By Radioisotope (2022 E)
Figure 74: APEJ Market Value Share, By Application (2022 E)
Figure 75: APEJ Market Value Share, By Source (2022 E)
Figure 76: APEJ Market Value Share, By End User (2022 E)
Figure 77: APEJ Market Value Share, By Country (2022 E)
Figure 78: APEJ Market Value Analysis (US$ Mn),2016-2021
Figure 79: APEJ Market Value Forecast (US$ Mn), 2022-2032
Figure 80: APEJ Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 81: APEJ Market Attractiveness Analysis by Application, 2022-2032
Figure 82: APEJ Market Attractiveness Analysis by Source, 2022-2032
Figure 83: APEJ Market Attractiveness Analysis by End User, 2022-2032
Figure 84: APEJ Market Attractiveness Analysis by Region, 2022-2032
Figure 85: Japan Market Value Share, By Radioisotope (2022 E)
Figure 86: Japan Market Value Share, By Application (2022 E)
Figure 87: Japan Market Value Share, By Source (2022 E)
Figure 88: Japan Market Value Share, By End User (2022 E)
Figure 89: Japan Market Value Analysis (US$ Mn),2016-2021
Figure 90: Japan Market Value Forecast (US$ Mn), 2022-2032
Figure 91: Japan Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 92: Japan Market Attractiveness Analysis by Application, 2022-2032
Figure 93: Japan Market Attractiveness Analysis by Source, 2022-2032
Figure 94: Japan Market Attractiveness Analysis by End User, 2022-2032
Figure 95: MEA Market Value Share, By Radioisotope (2022 E)
Figure 96: MEA Market Value Share, By Application (2022 E)
Figure 97: MEA Market Value Share, By Source (2022 E)
Figure 98: MEA Market Value Share, By End User (2022 E)
Figure 99: MEA Market Value Share, By Country (2022 E)
Figure 100: MEA Market Value Analysis (US$ Mn),2016-2021
Figure 101: MEA Market Value Forecast (US$ Mn), 2022-2032
Figure 102: MEA Market Attractiveness Analysis by Radioisotope, 2022-2032
Figure 103: MEA Market Attractiveness Analysis by Application, 2022-2032
Figure 104: MEA Market Attractiveness Analysis by Source, 2022-2032
Figure 105: MEA Market Attractiveness Analysis by End User, 2022-2032
Figure 106: MEA Market Attractiveness Analysis by Region, 2022-2032
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
